Abstract
In January 2019, a European Respiratory Society research seminar entitled “Targeting the detrimental effects of sleep disturbances and disorders” was held in Dublin, Ireland. It provided the opportunity to critically review the current evidence of pathophysiological responses of sleep disturbances, such as sleep deprivation, sleep fragmentation or circadian misalignment and of abnormalities in physiological gases such as oxygen and carbon dioxide, which occur frequently in respiratory conditions during sleep. A specific emphasis of the seminar was placed on the evaluation of the current state of knowledge of the pathophysiology of cardiovascular and metabolic diseases in obstructive sleep apnoea (OSA). Identification of the detailed mechanisms of these processes is of major importance to the field and this seminar offered an ideal platform to exchange knowledge, and to discuss pitfalls of current models and the design of future collaborative studies. In addition, we debated the limitations of current treatment strategies for cardiometabolic complications in OSA and discussed potentially valuable alternative approaches.
| Original language | English |
|---|---|
| Article number | 02295 |
| Journal | European Respiratory Journal |
| Volume | 56 |
| Issue number | 2 |
| ISSN | 0903-1936 |
| DOIs | |
| Publication status | Published - 01.08.2020 |
Funding
Acknowledgement: This perspective is based on the data presented and discussed during the European Respiratory Society (ERS) research seminar “Targeting the detrimental effects of sleep disturbances and disorders”. The seminar was organised by Silke Ryan (Dublin, Ireland, Chair) and Isaac Almendros (Barcelona, Spain, Co-Chair). The organisers would like to thank the faculty members, chairs and all participants for their active contribution, interaction and fruitful discussions (full presentations from the ERS research seminar can be downloaded from www.ers-education.org/events/ research-seminars.aspx and a list of all participants is available in the supplementary material). The seminar was sponsored by the ERS with additional financial support of unrestricted grants from ResMed PEI (Ireland), AirLiquide Conflict of interest: S. Ryan has nothing to disclose. E.P. Cummins has nothing to disclose. R. Farre has nothing to disclose. A. Gileles-Hillel has nothing to disclose. J.C. Jun has nothing to disclose. H. Oster has nothing to disclose. J-L. Pepin has nothing to disclose. D.W. Ray has nothing to disclose. S. Reutrakul reports grants from Merck Sharp and Dohme, personal fees from Medtronic and Sanofi Aventis, outside the submitted work. M. Sanchez-de-la-Torre has nothing to disclose. R. Tamisier reports travel grants from Agiradom, grants from Resmed, personal fees for lectures from Resmed, Philips and Elivie, personal fees for consultancy from Navigant, Inspire, Jazz Pharmaceutical and Resmed, outside the submitted work. I. Isaac Almendros has nothing to disclose.
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)
